Transcend Capital Advisors LLC Sells 6,857 Shares of Johnson & Johnson (NYSE:JNJ)

Transcend Capital Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 57,242 shares of the company’s stock after selling 6,857 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Johnson & Johnson were worth $8,278,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. IFS Advisors LLC lifted its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth $31,000. Bay Harbor Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter worth $35,000. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson during the 3rd quarter worth $40,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Guggenheim raised their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Bank of America cut their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

JNJ opened at $163.81 on Tuesday. The firm has a fifty day moving average price of $149.33 and a 200 day moving average price of $155.88. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market cap of $394.38 billion, a P/E ratio of 24.63, a P/E/G ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.